Project Grant F32CA298657
Award Date
9/10/25
Completion Date
3/9/28
Dollars Obligated
$245K
Federal Agency
National Cancer Institute
Awardee
Duke University (TP7EK8DZV6N5)
Federal Grant Program
93.398
Assistance Type
Project Grant
Place of Performance
North Carolina, USA
Similar Awards
This Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) will support research at Weill Medical College of Cornell University to investigate the role of the androgen receptor (AR) in both normal prostate cell function and prostate cancer development. The $564,543 award, effective March 1, 2025 through February 28, 2030, will enable the research team to determine the factors that mediate the switch between AR's normal, growth-suppressive...
This federal Project Grant award from the National Cancer Institute (NCI), under the Cancer Biology Research program (CFDA 93.396), provides $632,906 to Tulane University to conduct research on a novel role for the androgen receptor (AR) in prostate cancer progression and therapeutic resistance. The research aims to elucidate how AR's RNA-binding activity, rather than just its classical DNA-binding function, regulates the expression of key splicing factors that drive prostate cancer progression....
This $127,952 Project Grant award from the National Cancer Institute's Cancer Research Manpower program (CFDA 93.398) will support research at George Washington University to study the role of the enzyme HDAC11 in liver cancer progression. The research has two main aims: 1) to determine if HDAC11-mediated modifications to the splicing factor SF3B2 impact alternative mRNA splicing in liver cancer cells, and 2) to evaluate the potential of HDAC11-specific inhibitors as a new liver cancer treatment...
This federal Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $536,836.00 to The University of Texas M.D. Anderson Cancer Center to conduct research on the delivery optimization of a transarterial ablative therapy for treating hepatocellular carcinoma (HCC). The research aims to develop mathematical models that accurately describe the thermal, hypoxic, and pH response of this therapeutic approach in biological tissues, and to...
This $116,720 federal Project Grant award, provided by the National Cancer Institute (CFDA 93.398 Cancer Research Manpower program), will fund research to investigate the molecular basis of the interactions between the protein ABI1 and the androgen receptor (AR) in prostate cancer. The award will be used by the Research Foundation for the State University of New York, doing business as Upstate Medical Center, to conduct biophysical studies to elucidate how ABI1 binds to AR and affects its DNA...
The National Cancer Institute (NCI) awarded a $535,334 Project Grant (CFDA 93.396 - Cancer Biology Research) to the Albert Einstein College of Medicine to conduct research on the non-autonomous role of androgen signaling in prostate tumorigenesis. The project aims to investigate how androgen receptor (AR) activation in prostatic stromal cells, specifically those expressing the GLI1 transcription factor, can promote prostate epithelial oncogenesis and tumor development through paracrine signaling...
This Project Grant award, titled "EXPLOITING THERAPEUTIC VULNERABILITIES IN HEPATOCELLULAR CARCINOMA (ELEVATE)", is funded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research). The $2,678,459 award aims to advance the understanding of molecular mechanisms regulating non-alcoholic steatohepatitis (NASH)-associated hepatocellular carcinoma (HCC) and develop novel combinatorial treatment approaches. The award supports four research projects, an administrative core, a...
This $104,096 federal Project Grant award, provided by the National Cancer Institute (CFDA 93.398 Cancer Research Manpower program), supports research to identify genetic dependencies specific to subtypes of hepatocellular carcinoma (HCC). The project will utilize a hybrid in vivo and in silico approach to determine whether HCC genetic dependencies demonstrate subtype specificity based on pathomolecular features. Specific aims include: 1) using in vivo loss-of-function screening to assess...
This federal Project Grant award of $599,299 from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) supports research at the University of Illinois to investigate the role of the enzyme hexokinase 2 (HK2) in liver fibrosis and its connection to non-alcoholic steatohepatitis (NASH)-induced hepatocellular carcinoma (HCC). The research aims to further validate the importance of HK2 in liver fibrosis development and its impact on NASH-induced HCC, a leading cause of...
This Project Grant award from the National Cancer Institute's Cancer Research Manpower program (CFDA 93.398) is supporting research to develop novel inhibitors of the CYP8B1 protein, which plays a key role in the development of obesity-associated hepatocellular carcinoma (HCC). The $213,284 award to the Beckman Research Institute of the City of Hope will fund two aims: 1) Determining the role of CYP8B1 in obesity-associated HCC using mouse models, and 2) Performing chemical modifications and...